IPP Bureau

Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr
Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr

By IPP Bureau - November 08, 2025

Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025

Zydus Lifesciences secures FDA tentative approval for Olaparib tablets
Zydus Lifesciences secures FDA tentative approval for Olaparib tablets

By IPP Bureau - November 08, 2025

Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers

Alembic receives FDA final approval for Sumatriptan Injection USP
Alembic receives FDA final approval for Sumatriptan Injection USP

By IPP Bureau - November 08, 2025

Sumatriptan injection is indicated in adults for the acute treatment of migraine

Alembic announces USFDA final approval for Dasatinib Tablets
Alembic announces USFDA final approval for Dasatinib Tablets

By IPP Bureau - November 08, 2025

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets

Lupin Bioresearch Center receives zero observations from USFDA
Lupin Bioresearch Center receives zero observations from USFDA

By IPP Bureau - November 08, 2025

A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

By IPP Bureau - November 07, 2025

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
AstraZeneca invests additional $136 million to expand Qingdao inhalants facility

By IPP Bureau - November 07, 2025

This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT
MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

By IPP Bureau - November 07, 2025

Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions

By IPP Bureau - November 07, 2025

Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion

Amgen confident in US biosimilar market’s strength as sales surge 52%
Amgen confident in US biosimilar market’s strength as sales surge 52%

By IPP Bureau - November 07, 2025

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month
Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

By IPP Bureau - November 07, 2025

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies

FUJIFILM Sonosite unveils new portable ultrasound system ‘ Sonosite MT’
FUJIFILM Sonosite unveils new portable ultrasound system ‘ Sonosite MT’

By IPP Bureau - November 07, 2025

The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups

Philips reiterates FY25 outlook following steady Q3 performance
Philips reiterates FY25 outlook following steady Q3 performance

By IPP Bureau - November 07, 2025

Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year

Sovato secures series B funding to advance remote robotic surgery platform
Sovato secures series B funding to advance remote robotic surgery platform

By IPP Bureau - November 07, 2025

The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies

Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial
Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial

By IPP Bureau - November 07, 2025

VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus

Latest Stories

Interviews

Packaging